ciclosporin

ApprovedSmall molecule

Novartis

ciclosporin is one of 210 small molecule programs targeting Liver Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

209

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Skin CancerActive, not recruiting

KeratoconjunctivitisActive, not recruiting

ErythemaActive, not recruiting

LeprosyActive, not recruiting

Periodontal PocketActive, not recruiting

DermatitisActive, not recruiting

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

Tropical Spastic ParaparesisActive, not recruiting

Liver TransplantPhase 3

Active, not recruiting

Skin CancerApproved

Active, not recruiting

KeratoconjunctivitisPhase 2

Active, not recruiting

ErythemaPhase 2

Active, not recruiting

LeprosyPhase 2

Active, not recruiting

Periodontal PocketPhase 2

Active, not recruiting

DermatitisApproved

Active, not recruiting

PsoriasisPhase 3

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Tropical Spastic ParaparesisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

ciclosporin

Novartis

Approved

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Keratoconjunctivitis

NCT07169695

Q1 2029

Recruiting

Atopic Dermatitis

NCT05674695

Clinical

Trials by Indication[1]

Atopic Dermatitis4 trials

Long-term Study of Ciclosporin for Atopic Dermatitis

Completed· Novartis logo

Novartis·Phase 3·NCT00232063

Verification Study of Ciclosporin for Atopic Dermatitis

Completed· Novartis logo

Novartis·Phase 3·NCT00232076

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

Recruiting·FFundación Academia Española de Dermatología··NCT05674695·2,500 enrolled

Show 1 more trial

Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients

Completed·HHospices Civils de Lyon·Phase 3·NCT00809172·100 enrolled

Erythema2 trials

Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2·NCT00919776·20 enrolled

Ciclosporin in the Management of New Erythema Nodosum Leprosum

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2·NCT00919542·12 enrolled

Leprosy2 trials

Ciclosporin in the Management of New Type 1 Reactions in Leprosy

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2/3·NCT00919815·73 enrolled

Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 2·NCT00919451·16 enrolled

Liver Transplant1 trial

Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation

Terminated·RRennes University Hospital·Phase 3·NCT00375895·11 enrolled

Keratoconjunctivitis1 trial

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Not yet recruiting·LLaboratoires Thea·Phase 2·NCT07169695·120 enrolled

15 more indications

Concentration1 trial

A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03466567·21 enrolled

Psoriasis1 trial

Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients

Completed· Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals·Phase 3·NCT00408187·642 enrolled

Cardiac Surgery1 trial

Ciclosporin to Protect Renal Function In Cardiac Surgery

Completed·RRegion Skane·Phase 2·NCT02397213·155 enrolled

Periodontal Pocket1 trial

The Effect of Locally Delivered Ciclosporin as an Adjunct to Healing After Treatment of Periodontal Pockets

Completed·PPerioC Limited·Phase 2·NCT02366585·23 enrolled

Transplantation1 trial

Pilot Study of Unrelated Cord Blood Transplantation

Terminated·KKing's College Hospital NHS Trust·Phase 2·NCT00916045·40 enrolled

Injury1 trial

Ciclosporin to Reduce Reperfusion Injury in Primary PCI

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT02390674·54 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT06004752·30 enrolled

Newly Diagnosed1 trial

Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT06009497·44 enrolled

Treatment1 trial

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

Completed·PPeking Union Medical College Hospital·Phase 4·NCT05996393·86 enrolled

Adult1 trial

A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05155007·18 enrolled

Baricitinib1 trial

A Study of Baricitinib and Ciclosporin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01968057·18 enrolled

Tropical Spastic Paraparesis1 trial

Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

Completed·IImperial College London·Phase 2/3·NCT00773292·7 enrolled

Dermatitis1 trial

Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

Terminated·TTechnische Universität Dresden·Phase 4·NCT01231854·15 enrolled

Skin Cancer1 trial

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Terminated·—·Phase 4·NCT00866684·44 enrolled

Unspecified1 trial

The Vienna Prograf and Endothelial Progenitor Cell Study

Completed·MMedical University of Vienna·Phase 4·NCT00182559·148 enrolled

Sources

References

[1]
ClinicalTrials.gov — 25 trial records for ciclosporin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ciclosporin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ciclosporin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

ciclosporin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Trials by Indication[1]

Atopic Dermatitis4 trials

Erythema2 trials

Leprosy2 trials

Liver Transplant1 trial

Keratoconjunctivitis1 trial

Concentration1 trial

Psoriasis1 trial

Cardiac Surgery1 trial

Periodontal Pocket1 trial

Transplantation1 trial

Injury1 trial

Efficacy and Safety1 trial

Newly Diagnosed1 trial

Treatment1 trial

Adult1 trial

Baricitinib1 trial

Tropical Spastic Paraparesis1 trial

Dermatitis1 trial

Skin Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News